Oncology Central

Circulating tumor DNA: new horizons for improving cancer treatment

0

Recent cancer progress has been too slow [1,2]. Resistance to current therapeutics represents the major problem [3]. More recent developed technique of circulating tumor DNA (ctDNA) [4] detection and subsequently next-generation sequencing (NGS) application in these ‘fluid’ biopsies provides a partial explanation of therapeutic resistance due to the emergence of mutation. This mutational emerging heterogeneity assessment shapes a new roadmap for more effective therapeutic development [3].

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.